Home > News > Maternal Epithelial Ovarian Cancer
Gynaecological Oncology, Ovarian Cancer
Read Time: < 1 min

Maternal Epithelial Ovarian Cancer

Published Online: June 3rd 2011 European Oncology, 2009;5(1):64-6 DOI: https://doi.org/10.17925/EOH.2009.05.1.64
Authors: Julia Palmer, John Tidy, Manu Vatish
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Maternal epithelial ovarian cancer is rare; its rarity is reflected by the paucity of reported cases in the literature. Its incidence appears to be increased in the older pregnant patient, and since childbearing among older patients has markedly risen in more recent years it is likely that this disease will become more common. Currently, there are no definitive guidelines regarding patient management in maternal epithelial ovarian cancer. Management should therefore be case-dependent, individualised and multidisciplinary in nature. Data centralisation for individual cases including detailed information on clinico-pathological variables, treatment regimens, maternal and neonatal outcomes may be beneficial in identifying optimal management strategies in these rare tumours.

Article:

The Clinical Problem
Malignant epithelial ovarian cancer diagnosed during pregnancy is rare, with an estimated incidence of 1:12,000 to 1:50,000 pregnancies.1–3 A recent review4 identified 28 publications pertaining to maternal malignant epithelial ovarian cancer, spanning a time period of 49 years. The paucity of published data and low incidence of maternal epithelial ovarian cancer is likely to reflect the low prevalence of ovarian cancer in younger women. The incidence of maternal primary epithelial ovarian cancer appears to be increased in the older pregnant patient.4 In the UK there has been a two-fold increase in the birth rate in women >30 years of age and a three-fold increase in women >40 years of age since 1975.5 Similarly, in the US since 1980 the proportion of first births has increased three-fold in women ≥30 years of age, sixfold in women ≥35 years of age and 15-fold in women ≥40 years of age since 1980.6 Overall it is uncertain whether ovarian cancer associated with pregnancy is increasing,7 although this seems possible as childbearing among older patients increases.

Diagnosis
Patients may present with pain, abdominal distension or a mass, although many are asymptomatic at the time of detection.4 Approximately 50% of maternal epithelial ovarian cancers are detected as an incidental mass on routine pelvic or ultrasound examinations, with the majority detected in the first and second trimester. Detection at the time of Caesarean section or in the postnatal period is less common.4

To read full article please click here

Article Information:

Further Resources

Share this Article
Related Content In Ovarian Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72